Mutabilis is a privately-held French biopharmaceutical company developing novel non-beta-lactam PBP-targeting antibacterial drugs called dabocins to treat the most difficult-to-treat Gram-negative bacterial infections. Dabocins are derived from the non-natural diazabicyclooctane scaffold and show a remarkable stability to beta-lactamase hydrolysis. Mutabilis’ team has unique expertise in the derivatization and characterization of this scaffold. Mutabilis’ pipeline includes EBL-1463, a novel single-agent intravenous antibiotic against carbapenem-resistant Enterobacterales also supported by ENABLE (ND4BB/IMI), and 2G-DAB, a 2nd generation dabocin program supported by the Repair Impact Fund and which aims to discover the next generation dabocin covering both Enterobacterales and non-fermenters. For more information, please visit https://mutabilis.fr/.
View Top Employees from MutabilisWebsite | https://mutabilis.fr |
Employees | 27 (27 on RocketReach) |
Founded | 2004 |
Address | 102, Avenue Gaston Roussel, Romainville, Île-de-France 93230, FR |
Industry | Biotechnology Research, Media & Internet General, Media & Internet |
Looking for a particular Mutabilis employee's phone or email?
Wandrille Ract-Madoux is the CEO of Mutabilis.
27 people are employed at Mutabilis.
Mutabilis is based in Romainville, Île-de-France.